By Josh Beckerman
Zoetis said the U.S. Department of Agriculture's Center for Veterinary Biologics issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus.
The vaccine is labeled for use in chickens, the company said.
The USDA's Animal and Plant Health Inspection Service said Jan. 8 it would pursue a vaccine stockpile that matches current outbreak strains. In 2016, USDA created a vaccine stockpile for use in commercial poultry, though the vaccines at that time were never deployed. Zoetis received a contract award for the 2016 stockpile.
On Friday, Zoetis said that when a new strain was identified in the U.S. in early 2022, it immediately began work to update its previous vaccine.
The company's major products include Simparica, a chewable tablet for dogs that protects against ticks and fleas. In 2024, livestock revenue was about $2.9 billion out of $9.26 billion overall.
In January, Moderna announced that a $590 million government award to support development of bird flu vaccines.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 14, 2025 14:16 ET (19:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。